BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Silvestri A, Pin E, Huijbers A, Pellicani R, Parasido EM, Pierobon M, Petricoin E, Liotta L, Belluco C. Individualized therapy for metastatic colorectal cancer. J Intern Med 2013;274:1-24. [PMID: 23527888 DOI: 10.1111/joim.12070] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Dong N, Meng F, Wu Y, Wang M, Cui Y, Zhang S. Genetic polymorphisms in cytochrome P450 and clinical outcomes of FOLFIRI chemotherapy in patients with metastatic colorectal cancer. Tumor Biol 2015;36:7691-8. [DOI: 10.1007/s13277-015-3492-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
2 Cathomas G. PIK3CA in Colorectal Cancer. Front Oncol. 2014;4:35. [PMID: 24624362 DOI: 10.3389/fonc.2014.00035] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 6.5] [Reference Citation Analysis]
3 Jeong WJ, Cha PH, Choi KY. Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer. World J Gastroenterol 2014; 20(29): 9862-9871 [PMID: 25110417 DOI: 10.3748/wjg.v20.i29.9862] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
4 Abdul SN, Ab Mutalib NS, Sean KS, Syafruddin SE, Ishak M, Sagap I, Mazlan L, Rose IM, Abu N, Mokhtar NM, Jamal R. Molecular Characterization of Somatic Alterations in Dukes' B and C Colorectal Cancers by Targeted Sequencing. Front Pharmacol 2017;8:465. [PMID: 28769798 DOI: 10.3389/fphar.2017.00465] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
5 Lee YM, Kaduwal S, Lee KH, Park JC, Jeong WJ, Choi KY. Sur8 mediates tumorigenesis and metastasis in colorectal cancer. Exp Mol Med 2016;48:e249. [PMID: 27469030 DOI: 10.1038/emm.2016.58] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
6 Chow YP, Tan LP, Chai SJ, Abdul Aziz N, Choo SW, Lim PV, Pathmanathan R, Mohd Kornain NK, Lum CL, Pua KC, Yap YY, Tan TY, Teo SH, Khoo AS, Patel V. Exome Sequencing Identifies Potentially Druggable Mutations in Nasopharyngeal Carcinoma. Sci Rep 2017;7:42980. [PMID: 28256603 DOI: 10.1038/srep42980] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
7 Liu J, Li X, Yang S, Mou J, Lu H. Whole exome sequencing and transcriptome-wide profiling identify potentially subtype-relevant genes of nasopharyngeal carcinoma. Pathol Res Pract 2020;216:153244. [PMID: 33113455 DOI: 10.1016/j.prp.2020.153244] [Reference Citation Analysis]
8 Panczyk M. Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years. World J Gastroenterol 2014; 20(29): 9775-9827 [PMID: 25110414 DOI: 10.3748/wjg.v20.i29.9775] [Cited by in CrossRef: 74] [Cited by in F6Publishing: 75] [Article Influence: 9.3] [Reference Citation Analysis]
9 Huang L, Liu Z, Hu J, Luo Z, Zhang C, Wang L, Wang Z. MiR-377-3p suppresses colorectal cancer through negative regulation on Wnt/β-catenin signaling by targeting XIAP and ZEB2. Pharmacol Res 2020;156:104774. [PMID: 32220639 DOI: 10.1016/j.phrs.2020.104774] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
10 Yoon YS, Kim JC. Recent applications of chemosensitivity tests for colorectal cancer treatment. World J Gastroenterol 2014; 20(44): 16398-16408 [PMID: 25469008 DOI: 10.3748/wjg.v20.i44.16398] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
11 Poschau M, Dickreuter E, Singh-Müller J, Zscheppang K, Eke I, Liersch T, Cordes N. EGFR and β1-integrin targeting differentially affect colorectal carcinoma cell radiosensitivity and invasion. Radiother Oncol 2015;116:510-6. [PMID: 26096850 DOI: 10.1016/j.radonc.2015.06.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
12 Patil H, Saxena SG, Barrow CJ, Kanwar JR, Kapat A, Kanwar RK. Chasing the personalized medicine dream through biomarker validation in colorectal cancer. Drug Discov Today 2017;22:111-9. [PMID: 27693431 DOI: 10.1016/j.drudis.2016.09.022] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
13 Rosenblum D, Peer D. Omics-based nanomedicine: The future of personalized oncology. Cancer Letters 2014;352:126-36. [DOI: 10.1016/j.canlet.2013.07.029] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]